Primary Record
Limaprost
- In stock
- 8,123 g
- Purity
- 98.5 %
- CAS
- 74397-12-9
Compound Identifiers & Properties
- CAS
- 74397-12-9
- PubChem CID
- 6438378
- SMILES
- CCCC[C@H](C)C[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCC/C=C/C(=O)O)O)O
- Canonical SMILES
- CCCC[C@H](C)C[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC/C=C/C(=O)O
Names & Synonyms
- Limaprost
- limaprost alfadex
- Limaprostum
- 74397-12-9
- Opalmon
- Limaprost [INN]
- Prorenal
- Limaprostum [Latin]
- limaprost-alfadex
- Limaprost RS
- ONO 1206
- Limaprost (INN)
- Opalmon (TN)
- LIMAPROST [JAN]
- LIMAPROST [MI]
- AC1O5PKZ
- Ono-1206.alpha-CD
- Limaprost alfadex [JAN]
- RefChem:153454
- OP-1206.alpha-CD
- Prostaglandin Impurity 48
- D0N3NO
- LIMAPROST [MART.]
- Limaprost alpha-cyclodextrin
- ONO-1206
- LIMAPROST [WHO-DD]
- OP-1206
- 17S,20-Dimethyl-trans-delta2-PGE1
- C22H36O5
- SCHEMBL373011
- DTXSID701018146
- orb1707065
- CHEMBL2107456
- Limaprost, >=99%, crystalline
- OP 1206
- ONO1206
- CHEBI:135594
- MFCD00868275
- OJZYRQPMEIEQFC-UAWLTFRCSA-N
- DTXCID401476393
- GLXC-08154
- HMS3648D21
- UNII-L02U804092
- LIMAPROST ALFADEX [WHO-DD]
- EX-A4260
- HY-B0683
- ZINC4216741
- L02U804092
- Limaprost alpha-cyclodextrin clathrate
- 17S,20-Dimethyl-trans-2,3-didehydro-PGE1
- AKOS016010151
- C22-H36-O5
- CID6438378
- CS-2912
- DB09211
- FL59842
- CID:6438378
- NCGC00344134-02
- AC-37464
- AJ-48993
- J23.220C
- MS-26232
- SC-17267
- SID:134222144
- (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]hept-2-enoic acid
- DB-210725
- LS-125850
- FT-0630835
- NS00069853
- V1711
- 17-S-methyl-omega-homo-trans-delta(2)-PGE1
- D02722
- F85020
- LIMAPROST .ALPHA.-CYCLODEXTRIN CLATHRATE
- SBI-0654086.0001
- (2E,11-alpha,13E,15S,17S)-11,15-Dihydroxy-17,20-dimethyl-9-oxoprosta-2,13-dien-1-oic acid
- 17-S-methyl-omega-homo-trans-delta(2)-prostaglandin E1
- A850962
- C059238
- SR-01000946415
- (E)-7-((1R,2R,3R)-3-hydroxy-2-((3S,5S,E)-3-hydroxy-5-methylnon-1-en-1-yl)-5-oxocyclopentyl)hept-2-enoic acid
- SR-01000946415-1
- BRD-K25015158-001-01-2
- BRD-K25015158-001-02-0
- Q22075873
- 9-Oxo-11-alpha,15-alpha-dihydroxy-17S,20-dimethylprosta-trans-2,trans-13-dienoic acid
- 11ALPHA,15S-DIHYDROXY-17S,20-DIMETHYL-9-OXO-PROSTA
- 88852-12-4
- 2-Heptenoic acid, 7-((1R,2R,3R)-3-hydroxy-2-((1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl-5-oxocyclopentyl)-, (2E)-
- Prosta-2,13-dien-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-9-oxo-, (2E,11alpha,13E,15S,17S)-
- 11ALPHA,15S-DIHYDROXY-17S,20-DIMETHYL-9-OXO-PROSTA-2E,13E-DIEN-1-OIC ACID
- (2E)-7-((1R,2R,3R)-3-Hydroxy-2-((1E,3S,5S)-3-hydroxy-5-methylnon-1-en-1-yl)-5-oxocyclopentyl)hept-2-enoic acid
- (2E)-7-[(1R)-2beta-[(1E,3S,5S)-3-Hydroxy-5-methyl-1-nonenyl]-3alpha-hydroxy-5-oxocyclopentan-1alpha-yl]-2-heptenoic acid
- (2E)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonen-1-yl]-5-oxocyclopentyl]-2-heptenoic Acid
- (2E)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methylnon-1-en-1-yl]-5-oxocyclopentyl]hept-2-enoic acid
- (2E)-7-{(1R,2R,3R)-3-Hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methylnon-1-en-1-yl]-5-oxocyclopentyl}hept-2-enoic acid
- (2E)-7-{(1r,2r,3r)-3-hydroxy-2-[(1e,3s,5s)-3-hydroxy-5-methylnon-1-en-1-yl]-5-oxocyclopentyl}hept-2-enoic acid (non-preferred name)
- (2E,11alpha,13E,15S,17S)-11,15-Dihydroxy-17,20-dimethyl-9-oxoprosta-2,13-dien-1-oic acid
- (2E,11R,13E,15S,17S)-11alpha,15-Dihydroxy-17,20-dimethyl-9-oxoprosta-2,13-dien-1-oic acid
- (E)-7-((1R,2R,3R)-3-Hydroxy-2-((E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl)-2-heptenoic acid
- (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methyl-non-1-enyl]-5-oxo-cyclopentyl]hept-2-enoic acid
- 2-Heptenoic acid,7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonen-1-yl]-5-oxocyclopentyl]-,(2E)-
- 85679-52-3
- Prost-2,13-dien-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-9-oxo-, (2E,11-alpha,13E,15S,17S)-